Related Experiment Video
Updated: Aug 9, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
[Use of hypolipemic agents in Spain, 1987-2000]
M Siles Gutiérrez1, M Goldaracena Tanco, L Avila Muñoz
1Inspección Farmacéutica, Dirección Territorial del Insalud, Paseo María Agustín, 16 50004 Zaragoza. msiles@dtz.insalud.es
Revista Espanola De Salud Publica
|June 13, 2001
Summary
Lipid-reducing drug use in Spain significantly increased from 1987-2000, with statins becoming the dominant treatment. This trend impacted healthcare spending and therapeutic guidelines.
Area of Science:
- Pharmacoeconomics
- Health Services Research
Context:
- Lipid-reducing drugs represent a substantial portion of healthcare expenditure in Spain.
- The market for lipid-lowering medications is characterized by frequent shifts in molecular types.
Purpose:
- To analyze the consumption trends of lipid-reducing drugs within the Spanish National Health Care System from 1987 to 2000.
- To evaluate the economic impact and usage patterns of different lipid-reducing drug classes.
Summary:
- Prescription data for "Lipid-Reducing Preparations" (B04A) nationwide between 1987-2000 were analyzed.
- Total consumption reached over 389 billion pesetas (2.3 billion euros) and 2.58 billion Defined Daily Doses (DDD).
- Annual consumption and Treatment/Day Cost (TDC) increased, with statins emerging as the most consumed subgroup, accounting for 73.4% of total cost and 54.8% of DDDs.
Impact:
- Lipid-reducing drug consumption, including DDDs and cost, showed a consistent upward trajectory.
- The widespread adoption of statin therapy has significantly altered prescribing patterns and treatment guidelines for dyslipidemia in Spain.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...